Also trades as: 4519.T (JPX) · $vol 102M · CHGCF (OTC) · $vol 0M

$19.08

-0.25 (-1.29%)

Weekly Expected Move ±4.5%

$17 $18 $19 $20 $21

OTC · Healthcare · Drug Manufacturers - General · Tech Score Sell · Power 33 · $62.8B mcap · 640M float · 0.040% daily turnover · Short 27% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Income Trends

Revenue

$1.32T +12.7% ▲

5Y CAGR: +10.9%

Gross Profit

$937.6B +12.8% ▲

5Y CAGR: +12.8%

Operating Income

$618.8B +14.2% ▲

5Y CAGR: +15.5%

Net Income

$455.1B +17.5% ▲

5Y CAGR: +16.2%

EPS (Diluted)

$138.25 +17.5% ▲

5Y CAGR: +16.2%

EBITDA

$662.0B +15.4% ▲

5Y CAGR: +15.0%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$999.8B	$1.26T	$1.11T	$1.17T	$1.32T
YoY Growth	+27.0%	+26.0%	-11.8%	+5.3%	+12.7%
Cost of Revenue	$338.1B	$476.3B	$413.3B	$339.4B	$381.3B
Gross Profit	$661.6B	$783.7B	$698.1B	$831.2B	$937.6B
Gross Margin	66.2%	62.2%	62.8%	71.0%	71.1%
R&D Expenses	$137.3B	$149.6B	$174.9B	$181.4B	$196.7B
SG&A Expenses	$102.4B	$100.8B	$112.6B	$110.1B	$122.1B
Operating Expenses	$239.7B	$250.4B	$258.9B	$289.2B	$318.8B
Operating Income	$421.9B	$533.3B	$439.2B	$542.0B	$618.8B
Operating Margin	42.2%	42.3%	39.5%	46.3%	46.9%
Interest Expense	$48M	$61M	$0	-$1.0B	$1.1B
Income Before Tax	$419.4B	$531.2B	$443.8B	$543.0B	$626.8B
Tax Expense	$116.4B	$156.7B	$118.3B	$155.7B	$171.7B
Net Income	$303.0B	$374.4B	$325.5B	$387.3B	$455.1B
Net Margin	30.3%	29.7%	29.3%	33.1%	34.5%
EPS (Diluted)	$92.09	$113.79	$98.90	$117.68	$138.25
EBITDA	$450.3B	$564.7B	$470.9B	$573.7B	$662.0B
Shares Outstanding	3.29B	3.29B	3.29B	3.29B	3.29B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$315.7B	$302.1B	$288.5B	$290.0B	$339.0B	$401.5B	$327.7B	$346.1B
Cost of Revenue	$84.2B	$94.3B	$87.8B	$88.1B	$102.0B	$103.4B	$94.5B	$105.0B
Gross Profit	$231.5B	$207.8B	$200.6B	$201.9B	$237.0B	$298.0B	$233.2B	$241.1B
Gross Margin	73.3%	68.8%	69.6%	69.6%	69.9%	74.2%	71.2%	69.7%
R&D Expenses	$44.9B	$47.7B	$40.9B	$45.7B	$49.4B	$60.7B	$42.7B	$48.4B
SG&A Expenses	$27.8B	$32.4B	$23.2B	$28.4B	$5.3B	$65.2B	$24.8B	$29.4B
Operating Expenses	$71.1B	$86.7B	$64.0B	$74.3B	$54.7B	$90.9B	$67.5B	$78.4B
Operating Income	$160.4B	$121.1B	$136.7B	$127.7B	$182.3B	$172.5B	$165.7B	$162.7B
Operating Margin	50.8%	40.1%	47.4%	44.0%	53.8%	43.0%	50.6%	47.0%
Interest Expense	$0	$0	$0	$57M	$59M	$930M	$0	$0
Income Before Tax	$158.8B	$125.5B	$135.8B	$136.0B	$158.8B	$173.0B	$163.1B	$171.2B
Tax Expense	$49.3B	$33.9B	$38.6B	$38.8B	$45.6B	$48.7B	$45.6B	$53.4B
Net Income	$109.5B	$91.6B	$97.2B	$97.2B	$113.2B	$147.5B	$117.5B	$117.9B
Net Margin	34.7%	30.3%	33.7%	33.5%	33.4%	36.7%	35.9%	34.1%
EPS (Diluted)	$33.27	$27.81	$29.54	$29.52	$34.50	$44.82	$35.15	$35.52
EBITDA	$160.8B	$153.9B	$137.1B	$137.1B	$179.0B	$208.8B	$174.6B	$162.7B
Shares Outstanding	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B

CHGCY OTC

Income Trends

Profit Margins

Year-over-Year Growth

Sign in to InsiderStreet